THC BioMed Granted Licence to Produce Medical Marihuana by Health Canada

Destiny A. Lopez  |

THC Biomed (CSE:THC), a company devoted to research, analysis and development with regards to medical cannabis, announced today that the company has been granted a license to produce medical marihuana under Health Canada's Marihuana for Medical Purposes Regulations. This license gives THC Biomed the authority to to cultivate marihuana and to conduct research and development with medical marihuana.

"We are filled with emotion and pride and take this opportunity to thank our dedicated shareholders for helping us get to this point,” said John Miller, President and CEO of THC BioMed. Now we look forward to providing the highest quality product to our customers and value to our shareholders as we work diligently to build a world class cannabis company."

Prior to this milestone announcement, the company provided expertise to current and aspiring LP’s, offering support services such as full analytical services and an option for in-house training that includes:

  • Extraction Services
  • Horticulture training
  • Quality Assurance training
  • Consulting
  • Record Keeping / Documentation
  • Simulated Inspections

Also, through their Seeds R Us service, THC BioMed provides accessibility to an expansive inventory of superior genetic strains, with guaranteed consistency for aspiring Licensed Producers. Now, with this designation granted by Health Canada, THC BioMed can begin to close the divide between policy made by the governing regulatory body and the scientific research portion of medical cannabis.

Cannabis continues to be a hot topic in the medical, political and social realms. However, in recent years, support for the legalization of marihuana has increased due to its potential medical benefits. Consisting of 85 cannabinoids, these compounds have been shown to contain properties that are anti-inflammatory, anti-tumor, anti-nausea, anti-seizure, antipsychotic, and neuroprotective. One such cannabinoid, cannabidiol (CBD), a non-psychoactive cannabinoid, is believed to contain all the aforementioned medicinal benefits, as well as, properties that are pain relieving, bone stimulating, anti-anxiety, anti-diabetic, anti-spasmodic and anti-bacterial.

With medical marihuana being legalized across the globe, THC BioMed strives to be on the leading edge of scientific research and development of products and services related to this rapidly growing industry. This announcement of the company’s newly granted production license will not only allow the company to conduct vital research need to further legalization and remove social stigmas; it positions the company to also establish the industry’s commitment to high standards, scientific research, and effective product development.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
THC Tenet Healthcare Corporation 20.80 0.26 1.27 1,165,242 Trade



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…